Pharming Group
PHAR
9.65
-0.03
-0.31%
Pharming Group
US · PHAR
#3534 by market cap
Listed 2020
9.65
-0.03
-0.31%
Live - 5344 symbols - heartbeat 246s ago
· 2026-10-08 09:18
Pre-market
9.53
-1.28%
After-hours
9.65
0.00%
- Market cap
- 683.01M
- P/E (TTM)i
- 68.93
- P/Bi
- 2.52
- EPSi
- 0.04
- Div yieldi
- 0.00%
- 52W posi
- 1%
Reader sentiment
Are you bullish or bearish on PHAR?
Anonymous reader poll. Unscientific, not investment advice.
Recent news
-
CCORF Initiates Pharming Group(PHAR.US) With Buy Rating, Announces Target Price $37Market Newswire · 2026/4/10
-
Rating change
TR | OpenAI - 4o Maintains Pharming Group(PHAR.US) With Hold Rating, Cuts Target Price to $13Market Newswire · 2025/8/12
-
CCORF Maintains Pharming Group(PHAR.US) With Buy Rating, Maintains Target Price $38Market Newswire · 2026/9/30
-
Rating change
Pharming Group (PHAR) Receives a Buy From H.C. WainwrightTipRanks · 2026/1/28
-
Company notice
EXTRAWELL PHAR: FORM OF PROXY FOR USE BY SHAREHOLDERS AT THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 28 AUGUST 2026 AT 11:00 A.M.HKEX · 2026/7/30
-
Company notice
EXTRAWELL PHAR: FORM OF PROXY FOR USE BY SHAREHOLDERS AT THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 22 AUGUST 2025 AT 11:00 A.M.HKEX · 2025/7/28
-
CCORF Maintains Pharming Group(PHAR.US) With Buy Rating, Raises Target Price to $38Market Newswire · 2026/8/3
-
Rating change
Oppenheimer Maintains Pharming Group(PHAR.US) With Buy Rating, Cuts Target Price to $40Market Newswire · 2026/5/8
-
Rating change
Oppenheimer Maintains Pharming Group(PHAR.US) With Buy Rating, Raises Target Price to $42Market Newswire · 2025/11/7
-
H.C. Wainwright Maintains Pharming Group(PHAR.US) With Buy Rating, Maintains Target Price $37Market Newswire · 2026/9/30
-
Rating change
H.C. Wainwright Remains a Buy on Pharming Group (PHAR)TipRanks · 2025/11/7
-
Company notice
INNOVATIVE PHAR: RETIREMENT OF AUDITOR; AND WITHDRAWAL OF RESOLUTION NO. 3 AT THE ANNUAL GENERAL MEETING TO BE HELD ON THURSDAY, 29 AUGUST 2024HKEX · 2024/8/14
-
Rating change
Oppenheimer Maintains Pharming Group(PHAR.US) With Buy Rating, Maintains Target Price $42Market Newswire · 2026/2/4
-
Company notice
EXTRAWELL PHAR: FORM OF PROXY FOR SPECIAL GENERAL MEETING TO BE HELD ON TUESDAY, 15 OCTOBER 2024 AT 11:00 A.M.HKEX · 2024/9/26
-
Company notice
EXTRAWELL PHAR: FORM OF PROXY FOR SPECIAL GENERAL MEETING TO BE HELD ON FRIDAY, 28 MARCH 2025 AT 11:00 A.M.HKEX · 2025/3/12
-
Rating change
Oppenheimer Maintains Pharming Group(PHAR.US) With Buy Rating, Cuts Target Price to $41Market Newswire · 2026/3/13
-
Rating change
TR | OpenAI - 4o Upgrades Pharming Group(PHAR.US) to Buy Rating, Raises Target Price to $13.5Market Newswire · 2025/8/6
-
Rating change
Oppenheimer Maintains Pharming Group(PHAR.US) With Buy Rating, Raises Target Price to $41Market Newswire · 2025/8/1
-
CCORF Maintains Pharming Group(PHAR.US) With Buy Rating, Maintains Target Price $37Market Newswire · 2026/6/23
-
Rating change
TR | OpenAI - 4o Downgrades Pharming Group(PHAR.US) to Hold Rating, Raises Target Price to $14.5Market Newswire · 2025/8/11
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-10-08 09:18:35 · For reference only, not investment advice and not tailored to your situation.